David Linetsky - 06 Jan 2022 Form 4 Insider Report for Phreesia, Inc. (PHR)

Role
SVP, Life Sciences
Signature
/s/ Allison Hoffman by Power of Attorney for David Linetsky
Issuer symbol
PHR
Transactions as of
06 Jan 2022
Net transactions value
+$164,659
Form type
4
Filing time
07 Jan 2022, 15:16:47 UTC
Previous filing
09 Nov 2021
Next filing
19 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHR Common Stock Options Exercise $114,519 +24,314 +17% $4.71* 164,702 06 Jan 2022 Direct F1
transaction PHR Common Stock Options Exercise $4,465 +948 +0.58% $4.71* 165,650 06 Jan 2022 Direct F1
transaction PHR Common Stock Options Exercise $45,675 +5,688 +3.4% $8.03 171,338 06 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHR Stock Options (Right to buy) Options Exercise $0 -24,314 -81% $0.000000 5,689 06 Jan 2022 Common Stock 24,314 $4.71 Direct F2
transaction PHR Stock Options (Right to buy) Options Exercise $0 -948 -67% $0.000000 475 06 Jan 2022 Common Stock 948 $4.71 Direct F3
transaction PHR Stock Options (Right to buy) Options Exercise $0 -5,688 -50% $0.000000 5,689 06 Jan 2022 Common Stock 5,688 $8.03 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2 25% of this option vested and became exercisable on August 7, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
F3 25% of this option vested and became exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
F4 25% of this option vested and became exercisable on January 17, 2020, with the remainder vesting in three (3) equal annual installments thereafter.